Fate Therapeutics Inc
NASDAQ:FATE
Intrinsic Value
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. [ Read More ]
The intrinsic value of one FATE stock under the Base Case scenario is 0.6 USD. Compared to the current market price of 7.34 USD, Fate Therapeutics Inc is Overvalued by 92%.
Valuation Backtest
Fate Therapeutics Inc
Run backtest to discover the historical profit from buying and selling FATE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Fate Therapeutics Q4 Performance and Outlook
2023-Q4 Earnings Call
Fate Therapeutics has seen its revenue drop from $44.4 million to $1.7 million in Q4 compared to the prior year, mainly reflecting collaboration with Ono Pharmaceutical. R&D expenses fell by over 60% to $31.8 million, attributed to reduced salaries and benefits after restructuring, while G&A expenses decreased by 17% to $17.9 million. Despite this, the company maintains a strong financial position with $316 million in cash and investments. The net loss for the quarter was $44.1 million, or $0.45 per share. Updates on FT522 without conditioning chemotherapy and the multiple myeloma program FT576 are expected in the second half of 2024 and mid-year, respectively.
Balance Sheet Decomposition
Fate Therapeutics Inc
Current Assets | 331.5m |
Cash & Short-Term Investments | 315.2m |
Receivables | 1.8m |
Other Current Assets | 14.5m |
Non-Current Assets | 174.7m |
Long-Term Investments | 980k |
PP&E | 158.5m |
Other Non-Current Assets | 15.2m |
Current Liabilities | 39.1m |
Accounts Payable | 4.7m |
Accrued Liabilities | 33.7m |
Other Current Liabilities | 685k |
Non-Current Liabilities | 98.7m |
Other Non-Current Liabilities | 98.7m |
Earnings Waterfall
Fate Therapeutics Inc
Revenue
|
63.5m
USD
|
Operating Expenses
|
-254m
USD
|
Operating Income
|
-190.5m
USD
|
Other Expenses
|
29.6m
USD
|
Net Income
|
-160.9m
USD
|
Free Cash Flow Analysis
Fate Therapeutics Inc
What is Free Cash Flow?
FATE Profitability Score
Profitability Due Diligence
Fate Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Fate Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
FATE Solvency Score
Solvency Due Diligence
Fate Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Fate Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FATE Price Targets Summary
Fate Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for FATE is 7.68 USD with a low forecast of 2.02 USD and a high forecast of 12.6 USD.
Ownership
FATE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FATE Price
Fate Therapeutics Inc
Average Annual Return | 63.88% |
Standard Deviation of Annual Returns | 201.51% |
Max Drawdown | -99% |
Market Capitalization | 723.9m USD |
Shares Outstanding | 99 237 504 |
Percentage of Shares Shorted | 17.4% |
FATE News
Last Important Events
Fate Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Fate Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 449 full-time employees. The company went IPO on 2013-10-01. The firm is focused on the development of programmed cellular immunotherapies for patients with cancer. The company uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The firm is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The firm's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
Contact
IPO
Employees
Officers
The intrinsic value of one FATE stock under the Base Case scenario is 0.6 USD.
Compared to the current market price of 7.34 USD, Fate Therapeutics Inc is Overvalued by 92%.